A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study

The aim of this phase I study was to assess feasibility, pharmacokinetics and toxicity of methoxymorpholino doxorubicin (MMRDX or PNU-152243) administered as a 3 h intravenous infusion once every 4 weeks. Fourteen patients with intrinsically anthracycline-resistant tumours received 37 cycles of MMRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokkema, E, Verweij, J, van Oosterom, A T, Uges, D R A, Spinelli, R, Valota, O, de Vries, E G E, Groen, H J M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374418/
https://www.ncbi.nlm.nih.gov/pubmed/10732743
http://dx.doi.org/10.1054/bjoc.1999.0996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374418/
https://www.ncbi.nlm.nih.gov/pubmed/10732743
http://dx.doi.org/10.1054/bjoc.1999.0996

Ejemplares similares